Kvantify

Kvantify is a Danish software company, started in 2022, that develops software running on both quantum computers and classical compute architectures such as CPUs and GPUs, aimed at chemistry and biology problems in molecular and drug discovery. Its algorithms are designed to distribute calculations across the appropriate quantum or classical backend in high-performance computing environments, on the premise that quantum and classical machines will complement rather than replace each other: quantum computation supplies accurate results that feed AI or physics-based classical models covering large chemical and biological spaces.

The company has a particular focus on the life science industry, especially early drug discovery, and offers two named products. Qrunch, launched in November 2025, lets chemists set up and run quantum chemistry calculations on cloud quantum hardware or local simulators without specialized quantum training, using standard chemistry terminology, a fluent builder-pattern user interface, and hardware-agnostic execution; published showcases span drug selectivity (Cathepsin-K, 80 qubits), drug toxicity (nitrosamines, 40 qubits), carbon capture (COF-999, 54 qubits), bioremediation (dehalogenase, 40 qubits), battery chemistry (butyronitrile, 50 qubits) and enzymatic catalysis and electrolyte ionization accuracies below 1 kcal/mol. Koffee Unbinding Kinetics is a classical-computing drug discovery product that produces physics-based protein-ligand residence time estimates in roughly 1-2 minutes per complex on a GPU without machine learning or target-specific fine-tuning, with use cases in reducing off-target toxicity, assessing binding-site mutations, kinetics rescoring in virtual screening, and PROTAC design; it is documented in a JCIM paper and a preprint and offered with a command-line interface plus a beta graphical interface with a 3D viewer.

Founding story

Kvantify was founded by Allan Grønlund, Hans Henrik Knudsen and Nikolaj T. Zinner as an academic spinout, with the ambition of addressing complex computational challenges in industry through quantum computing. After an initial scoping phase in late 2021, the company was incorporated in early 2022 with an unusually large angel investment as startup capital, used to build a team working across life science, chemistry, logistics, finance and other verticals.

Business model

Kvantify sells software products for quantum and classical computers, with licensing arrangements indicated for its Qrunch technology (a free version plus paid licenses and published pricing) and trial licenses for Koffee Unbinding Kinetics. It has also combined product development with grant-funded research projects and collaborative partnerships with drug discovery organizations.

Software licensing: Qrunch is offered with a downloadable free version alongside paid licenses and pricing tiers, and Koffee Unbinding Kinetics is made available through trial licenses arranged by contacting the company.

Traction

Qrunch showcases report calculations at 40-80 qubits across drug selectivity, toxicity, carbon capture, bioremediation and battery chemistry problems, with sub-1 kcal/mol accuracy claims for enzymatic catalysis and electrolyte ionization. Koffee results include ranking correlations against experimental residence times from public datasets covering kinases, GPCRs and chaperones, and a preprint describing a prospective real-world drug discovery project predicting binding modes and ranking compounds by residence time. The company has raised institutional venture funding and secured EIC and Innovation Fund Denmark grants.

Latest developments

On 5 March 2026 Kvantify announced the second close of a funding round totaling €7 million, with participation from the European Innovation Council Fund and Delphinus Venture Capital, earmarked for commercializing its hybrid quantum-classical software stack and expanding Qrunch, which launched in November 2025. In 2025 the company appointed Dr. Jörg Weiser, former Managing Director at Schrödinger, as Executive Chairperson of the Board and increased its focus on productization and commercialization.